Multi-Target immune cell attack on tough blood cancers
NCT ID NCT03125577
Summary
This study is testing a new combination of engineered immune cells, called CAR-T cells, designed to attack B-cell cancers like leukemia and lymphoma. It aims to improve treatment for patients whose cancer has come back or hasn't responded to standard therapies by targeting up to seven different markers on cancer cells at once. The main goals are to see if this approach is safe and if it can effectively reduce or eliminate the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center
RECRUITINGKunming, Yunnan, 650000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhujiang Hospital of Southern Medical University
RECRUITINGGuangzhou, Guangdong, 510282, China
-
Zhujiang Hospital of Southern Medical University
RECRUITINGGuangzhou, Guangdong, 510282, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.